Therapeutic Vaccine Strategies against Human Papillomavirus.

PubWeight™: 0.89‹?›

🔗 View Article (PMC 4494257)

Published in Vaccines (Basel) on June 13, 2014

Authors

Hadeel Khallouf1, Agnieszka K Grabowska2, Angelika B Riemer3

Author Affiliations

1: Immunotherapy and -prevention, German Cancer Research Center (DKFZ), Heidelberg 69120, Germany. h.khallouf@dkfz.de.
2: Immunotherapy and -prevention, German Cancer Research Center (DKFZ), Heidelberg 69120, Germany. a.grabowska@dkfz.de.
3: Immunotherapy and -prevention, German Cancer Research Center (DKFZ), Heidelberg 69120, Germany. a.riemer@dkfz.de.

Associated clinical trials:

Vaccine Therapy With or Without Imiquimod in Treating Patients With Grade 3 Cervical Intraepithelial Neoplasia | NCT00788164

Safety Study of HPV DNA Vaccine to Treat Head and Neck Cancer Patients | NCT01493154

A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3 (HPV-003) | NCT01304524

Therapeutic Vaccination for Patients With HPV16+ Cervical Intraepithelial Neoplasia (CIN2/3) | NCT00988559

MAGE-A3/HPV 16 Vaccine for Squamous Cell Carcinoma of the Head and Neck | NCT00257738

Safety Study of Recombinant Listeria Monocytogenes(Lm)Based Vaccine Virus Vaccine to Treat Oropharyngeal Cancer (REALISTIC:) | NCT01598792

Vaccine Therapy in Treating Patients With Persistent or Recurrent Cervical Cancer | NCT01266460

An Assessment of an Attenuated Live Listeria Vaccine in CIN 2+ (ADXS11-001) | NCT01116245

Vaccine Therapy in Preventing Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia | NCT00121173

Phase II Study of HPV Therapeutic Vaccine in HPV Infected Women With Normal Cytology or ASCUS/LSIL (RHEIA-VAC) | NCT01957878

A Phase I Clinical Trial of an HPV Therapeutic Vaccine | NCT01653249

A Study of RO5217790 in Participants With High Grade Cervical Intraepithelial Neoplasia (CIN) Associated With High Risk Human Papillomavirus (HR-HPV) Infection | NCT01022346

Articles cited by this

(truncated to the top 100)

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer (2010) 90.16

Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34

A Toll-like receptor recognizes bacterial DNA. Nature (2000) 26.34

The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science (1989) 16.54

Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer (2002) 15.46

SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics (1999) 14.15

A review of human carcinogens--Part B: biological agents. Lancet Oncol (2009) 13.85

Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science (1990) 12.88

Human papillomavirus and cervical cancer. Lancet (2007) 12.47

Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol (2010) 9.86

Regulation of adaptive immunity by the innate immune system. Science (2010) 8.00

Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol (2008) 7.18

Systems biology of vaccination for seasonal influenza in humans. Nat Immunol (2011) 6.09

Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med (2009) 5.79

Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst (2000) 5.32

Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism. Immunogenetics (1999) 4.88

DNA vaccines: immunology, application, and optimization*. Annu Rev Immunol (2000) 4.51

Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J Exp Med (2008) 4.21

A community resource benchmarking predictions of peptide binding to MHC-I molecules. PLoS Comput Biol (2006) 3.73

The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov (2012) 3.60

Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. Int J Cancer (2006) 3.38

Vaccine adjuvants: current state and future trends. Immunol Cell Biol (2004) 2.74

More than one reason to rethink the use of peptides in vaccine design. Nat Rev Drug Discov (2007) 2.68

Cervical cancer prevention: new tools and old barriers. Cancer (2010) 2.68

Pathogen recognition in the innate immune response. Biochem J (2009) 2.64

A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet (1996) 2.59

Heat shock proteins and immune system. J Leukoc Biol (2009) 2.54

Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. Adv Drug Deliv Rev (2009) 2.54

NN-align. An artificial neural network-based alignment algorithm for MHC class II peptide binding prediction. BMC Bioinformatics (2009) 2.50

Smallpox vaccination: a review, part II. Adverse events. Clin Infect Dis (2003) 2.46

Systems vaccinology. Immunity (2010) 2.36

Vaccines for the twenty-first century society. Nat Rev Immunol (2011) 2.34

Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer (2008) 2.31

The cancer vaccine roller coaster. Nat Biotechnol (2009) 2.26

Electroporation delivery of DNA vaccines: prospects for success. Curr Opin Immunol (2011) 2.25

Mucosal imprinting of vaccine-induced CD8⁺ T cells is crucial to inhibit the growth of mucosal tumors. Sci Transl Med (2013) 2.15

Systems biology in immunology: a computational modeling perspective. Annu Rev Immunol (2011) 2.15

Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16. J Immunol (2001) 2.13

Use of defined TLR ligands as adjuvants within human vaccines. Immunol Rev (2011) 2.09

Systems scale interactive exploration reveals quantitative and qualitative differences in response to influenza and pneumococcal vaccines. Immunity (2013) 2.08

Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. J Immunol (1994) 2.07

Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin Cancer Res (2008) 2.06

Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. J Immunol (2008) 2.00

Infection-mimicking materials to program dendritic cells in situ. Nat Mater (2009) 2.00

Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation. J Clin Oncol (2009) 1.98

Learning immunology from the yellow fever vaccine: innate immunity to systems vaccinology. Nat Rev Immunol (2009) 1.94

Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol (2002) 1.93

The first clinical use of a live-attenuated Listeria monocytogenes vaccine: a Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix. Vaccine (2009) 1.92

At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. J Leukoc Biol (2013) 1.90

Adenovirus vectors for gene delivery. Curr Opin Biotechnol (1999) 1.89

Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia. Br J Cancer (2010) 1.89

Twin studies of immunogenicity--determining the genetic contribution to vaccine failure. Vaccine (2001) 1.88

Cross-roads in the classification of papillomaviruses. Virology (2013) 1.87

Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses. Sci Transl Med (2012) 1.84

Viral vectors as vaccine platforms: deployment in sight. Curr Opin Immunol (2011) 1.80

A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3. Clin Cancer Res (2009) 1.79

NetMHCIIpan-2.0 - Improved pan-specific HLA-DR predictions using a novel concurrent alignment and weight optimization training procedure. Immunome Res (2010) 1.78

Engineering nano- and microparticles to tune immunity. Adv Mater (2012) 1.75

Apoptosis and other immune biomarkers predict influenza vaccine responsiveness. Mol Syst Biol (2013) 1.75

Lentiviral vectors with a defective integrase allow efficient and sustained transgene expression in vitro and in vivo. Proc Natl Acad Sci U S A (2006) 1.74

Antibodies against the human papillomavirus type 16 early proteins in human sera: correlation of anti-E7 reactivity with cervical cancer. J Natl Cancer Inst (1989) 1.72

A naturally selected dimorphism within the HLA-B44 supertype alters class I structure, peptide repertoire, and T cell recognition. J Exp Med (2003) 1.72

Enhancing DNA vaccine potency by coadministration of DNA encoding antiapoptotic proteins. J Clin Invest (2003) 1.71

Cytolytic CD4 cells: Direct mediators in infectious disease and malignancy. Cell Immunol (2010) 1.69

Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses. Proc Natl Acad Sci U S A (2010) 1.67

Early patterns of gene expression correlate with the humoral immune response to influenza vaccination in humans. J Infect Dis (2011) 1.67

Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin Cancer Res (2008) 1.66

In situ regulation of DC subsets and T cells mediates tumor regression in mice. Sci Transl Med (2009) 1.65

Enhanced humoral and Type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion. Vaccine (2009) 1.60

Keyhole limpet hemocyanin (KLH): a biomedical review. Micron (1999) 1.56

Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination. Clin Cancer Res (2004) 1.51

Toll-like receptor ligands synergize through distinct dendritic cell pathways to induce T cell responses: implications for vaccines. Proc Natl Acad Sci U S A (2008) 1.51

Adjuvants for cancer vaccines. Semin Immunol (2010) 1.48

Human papillomavirus genome variants. Virology (2013) 1.45

Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial. Eur J Cancer (1999) 1.44

Myeloid and plasmacytoid dendritic cells are susceptible to recombinant adenovirus vectors and stimulate polyfunctional memory T cell responses. J Immunol (2007) 1.44

A mouse model of human adaptive immune functions: HLA-A2.1-/HLA-DR1-transgenic H-2 class I-/class II-knockout mice. Eur J Immunol (2004) 1.43

Rapid, efficient functional characterization and recovery of HIV-specific human CD8+ T cells using microengraving. Proc Natl Acad Sci U S A (2012) 1.41

Integrative genomic analysis of the human immune response to influenza vaccination. Elife (2013) 1.37

Engineering approaches to immunotherapy. Sci Transl Med (2012) 1.36

Prediction of epitopes using neural network based methods. J Immunol Methods (2010) 1.35

Modification of professional antigen-presenting cells with small interfering RNA in vivo to enhance cancer vaccine potency. Cancer Res (2005) 1.32

A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin Cancer Res (2000) 1.32

From crucial to negligible: functional CD8⁺ T-cell responses and their dependence on CD4⁺ T-cell help. Eur J Immunol (2012) 1.27

Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine. Vaccine (2002) 1.25

Viral vectors: a look back and ahead on gene transfer technology. New Microbiol (2013) 1.25

Natural T-helper immunity against human papillomavirus type 16 (HPV16) E7-derived peptide epitopes in patients with HPV16-positive cervical lesions: identification of 3 human leukocyte antigen class II-restricted epitopes. Int J Cancer (2001) 1.25

Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins. Cancer Res (2003) 1.24

Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer. Clin Cancer Res (2002) 1.22

ZYC101a for treatment of high-grade cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol (2004) 1.22

Intramuscular therapeutic vaccination targeting HPV16 induces T cell responses that localize in mucosal lesions. Sci Transl Med (2014) 1.21

Nanoparticle conjugation of CpG enhances adjuvancy for cellular immunity and memory recall at low dose. Proc Natl Acad Sci U S A (2013) 1.20

Therapeutic vaccination with papillomavirus E6 and E7 long peptides results in the control of both established virus-induced lesions and latently infected sites in a pre-clinical cottontail rabbit papillomavirus model. Vaccine (2005) 1.20

Immunotherapy for cervical cancer: Research status and clinical potential. BioDrugs (2010) 1.18

Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial. J Virol (2007) 1.18

Systems biology approaches to new vaccine development. Curr Opin Immunol (2011) 1.17

Randomized controlled trial of an adjuvanted human papillomavirus (HPV) type 6 L2E7 vaccine: infection of external anogenital warts with multiple HPV types and failure of therapeutic vaccination. J Infect Dis (2005) 1.17

Increased gene expression and inflammatory cell infiltration caused by electroporation are both important for improving the efficacy of DNA vaccines. J Biotechnol (2004) 1.16

Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus. Hum Gene Ther (2004) 1.16

Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a Phase I study of ZYC101. Clin Cancer Res (2002) 1.15